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Background: Intramyocardial injection of human bone marrow-derived MSCs has been demonstrated to improve cardiac function in experimental 
acute myocardial infarction (AMI) models. However, the effect of intramyocardial MSC treatment in AMI patients is unknown. Therefore, we 
investigated the short and long term effect of intramyocardial autologous bone marrow-derived, ex vivo expanded, mesenchymal stem cell (MSCs) 
injection in patients with recent AMI, on safety and the effect on cardiac function and perfusion.
Methods: Nine patients (59±8 years, 7 male) with a first ST-elevation AMI, successfully treated with primary percutaneous transluminal coronary 
angioplasty, were included. Bone marrow was aspirated 2 days post AMI and MSCs were cultured for 14 days followed by intramyocardial injection 
into ischemic and/or peri-infarct regions (NOGA). Safety assessment included peri-procedural blood sampling and holter recordings at short and 
long term follow up. Gated Tc-99m tetrofosmin single-photon emission computed tomography (g-SPECT) was performed to evaluate myocardial 
perfusion and function at baseline, 3 months and 3 years follow up.
Results: There were no peri-procedural signs of inflammation, arrhythmias or myocardial infarction. Holter recordings showed no occurrence 
of ventricular arrhythmias in both short and long term follow up. One patient experienced a transient ischemic attack shortly after the injection 
procedure, 1 patient died at 7 months due to heart failure and 1 patient was revascularized after 4 months follow up. Evaluation of SPECT 
demonstrated an improvement in summed stress score from 30.8±6.7 at baseline to 28.2±7.9 at 3 months (p=0.02) and 26.8±6.7 at 3 years 
(p=0.02). Summed rest score also improved at 3 months and 3 years (29.9±7.3 to 28.0±8.0 [p=0.04] and to 25.5±7.1 [p<0.01] respectively). 
Evaluation of left ventricular ejection fraction showed no significant improvements.
Conclusion: In short and long term evaluation, intramyocardial injection of MSCs in patients with recent AMI demonstrated to be safe and showed 
improvements in myocardial perfusion up to 3 years after injection.
